Table 1.
Baseline Patient Characteristics
| Characteristic | (n = 245 patients)*† |
|---|---|
| Age, years | 40 [31–58] |
| Male | 101 (41.2) |
| BMI, kg/m2 | 25.8 [22.4–30.2] |
| CrCl, mL/min | 97 [71.5–120] |
| Pertinent medical/social history | |
| Atrial fibrillation | 10 (4.1) |
| Bundle branch block | 6 (2.5) |
| On pacemaker | 6 (2.5) |
| Psychological disorders (anxiety/depression/bipolar) | 105 (42.9) |
| Coronary artery disease | 21 (8.6) |
| Cannabis use | 93 (37.9) |
| Other substance abuse | 47 (19.2) |
| Alcohol abuse | 47 (19.2) |
| Baseline QTc, milliseconds | 447 [428–465] |
| QT prolongation predisposing risk factors at baseline | |
| Age > 65 | 39 (15.9) |
| HFrEF | 7 (2.8) |
| Myocardial infarction | 13 (5.3) |
| Bradycardia | 22 (8.9) |
| Hypokalemia | 47 (19.1) |
| Hypomagnesemia | 33 (13.4) |
| Use of QTc-prolonging medications | |
| 4 h before droperidol administration | 102 (31.2) |
| 4 h after droperidol administration | 45 (13.9) |
| Indication for droperidol administration# | |
| Agitation | 61 (24.9) |
| Headache | 5 (2) |
| Nausea/vomiting | 122 (49.8) |
| Cannabinoid hyperemesis syndrome | 64 (26.1) |
| Abdominal pain | 86 (35.1) |
| Other/unknown | 1 (0.5) |
*data expressed as median [IQR], †data expressed as n (%)
#some patients had more than one indication
Abbreviations: BMI, body mass index; CrCl, creatinine clearance; HFrEF, heart failure with reduced ejection fraction